Ken Griffin 2seventy Bio, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 40,400 shares of TSVT stock, worth $155,540. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,400
Previous 4,512
795.39%
Holding current value
$155,540
Previous $19,000
1036.84%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding TSVT
# of Institutions
128Shares Held
47.8MCall Options Held
84.3KPut Options Held
53.7K-
Kynam Capital Management, LP Princeton, NJ5.95MShares$22.9 Million3.34% of portfolio
-
Morgan Stanley New York, NY4.36MShares$16.8 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY4.22MShares$16.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.91MShares$15 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.73MShares$14.4 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $146M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...